How Can Second-Line Therapy for Metastatic Renal Cell Carcinoma Help to Define an Overall Management Strategy?

Publisher： Karger

E-ISSN： 1423-0232|77|2|82-91

ISSN： 0030-2414

Source： Oncology, Vol.77, Iss.2, 2009-07, pp. : 82-91

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Irinotecan in Second-Line Therapy of Metastatic Colorectal Cancer

By  

Oncology Research and Treatment, Vol. 23, Iss. 4, 2000-05 ,pp. : 15-17

Karger

Access to resources Recommend Favorite

Retrospective Analysis of Fifth-Line Targeted Therapy Efficacy in Patients with Metastatic Renal Cell Carcinoma

By  

Urologia Internationalis, Vol. 98, Iss. 2, 2016-03 ,pp. : 184-190

Karger

Access to resources Recommend Favorite

Long-Term Survival after Second-Line Therapy with Docetaxel and Carboplatin and Monthly Pamidronic Acid in a Woman with Metastatic Non-Small Cell Lung Cancer

By  

Oncology Research and Treatment, Vol. 29, Iss. 5, 2006-05 ,pp. : 206-208

Karger

Access to resources Recommend Favorite

PSA and Second-Line Therapy of Hormone Refractory Prostate Carcinoma

By  

Urologia Internationalis, Vol. 66, Iss. 3, 2001-04 ,pp. : 131-134

Karger

Access to resources Recommend Favorite

Continuous Therapy with Sunitinib in Patients with Metastatic Renal Cell Carcinoma

By  

Oncology Research and Treatment, Vol. 31, Iss. 8-9, 2008-07 ,pp. : 485-485

Karger

Access to resources Recommend Favorite